Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

11.50USD
15 Aug 2018
Change (% chg)

$-0.30 (-2.54%)
Prev Close
$11.80
Open
$11.70
Day's High
$11.70
Day's Low
$11.35
Volume
236,388
Avg. Vol
224,224
52-wk High
$17.30
52-wk Low
$7.25

Latest Key Developments (Source: Significant Developments)

TG Therapeutics Inc QTRLY Loss Per Share $0.59
Tuesday, 7 Aug 2018 04:00pm EDT 

Aug 7 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.TG THERAPEUTICS INC QTRLY LOSS PER SHARE $0.59.TG THERAPEUTICS - CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, AND INTEREST RECEIVABLE WERE $126.3 MILLION AS OF JUNE 30, 2018.TG THERAPEUTICS - CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, INTEREST RECEIVABLE ON HAND AT QUARTER END ENOUGH TO FUND PLANNED OPERATIONS INTO H2 2019.  Full Article

TG Therapeutics Reports Qtrly Loss Per Share Of $0.59
Tuesday, 8 May 2018 07:30am EDT 

May 8 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, AND INTEREST RECEIVABLE WERE $109.2 MILLION AS OF MARCH 31, 2018.QTRLY LOSS PER SHARE $0.59.Q1 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.TG THERAPEUTICS-CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, INTEREST RECEIVABLE ON HAND AS OF MARCH 31, SUFFICIENT TO FUND OPERATIONS THROUGH MID-2019.  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

TG Therapeutics Announces Initiation Of Randomized Phase II Trial In Follicular Lymphoma
Monday, 27 Nov 2017 07:30am EST 

Nov 27 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES INITIATION OF NATIONAL CANCER INSTITUTE/SWOG-SPONSORED RANDOMIZED PHASE II TRIAL IN FOLLICULAR LYMPHOMA.  Full Article

TG Therapeutics qtrly net loss per common share $0.48
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - TG Therapeutics Inc ::TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results.TG therapeutics inc - qtrly net loss per common share $0.48.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.TG therapeutics inc - believes cash and cash equivalents will be sufficient to fund planned operations through 2018​.  Full Article

TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial
Monday, 16 Oct 2017 07:30am EDT 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial.TG Therapeutics Inc - ‍targeting an NDA/BLA filing for combination of TGR-1202 + TG-1101 in 2H18​.TG Therapeutics Inc - ‍top-line ORR data from UNITY-CLL trial expected in 2Q18​.  Full Article

TG Therapeutics ‍says FDA confirms accelerated approval for TG-1101 based on overall response rate a review issue
Monday, 16 Oct 2017 07:30am EDT 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics provides update on fda meeting for genuine phase 3 trial.TG Therapeutics - co ‍has met with U.S. FDA regarding use of results from genuine phase 3 trial to support bla filing for approval of TG-1101​.TG Therapeutics Inc - ‍fda confirmed that accelerated approval for TG-1101 based on overall response rate would be a review issue ​.TG Therapeutics - ‍FDA asked co to consider future available therapy in risk/benefit analysis in future BLA filing that may impact accelerated approval.TG Therapeutics - co, FDA also discussed potential use of progression free survival results from genuine trial to support full approval of TG-1101​.TG Therapeutics Inc - ‍plans to have a follow-up meeting with FDA to discuss use of PFs endpoint in more detail before end of year​.  Full Article

TG Therapeutics says phase 3 ULTIMATE trials evaluating TG-1101 in multiple sclerosis patients are now open for enrollment
Friday, 15 Sep 2017 07:30am EDT 

Sept 15 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc announces the phase 3 ultimate trials evaluating tg-1101 in patients with multiple sclerosis are now open for enrollment.TG Therapeutics Inc - ‍ ULTIMATE I and ULTIMATE II phase 3 trials will each enroll approximately 440 subjects, randomized in a 1:1 ratio.  Full Article

TG Therapeutics announces completion of target enrollment
Tuesday, 5 Sep 2017 07:30am EDT 

Sept 5 (Reuters) - TG Therapeutics Inc ::TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial.TG Therapeutics Inc - ‍unity-CLL phase 3 trial is being conducted pursuant to a special protocol assessment (SPA) agreement with FDA.TG Therapeutics Inc - ‍enrollment is expected to continue until mid-October​.TG Therapeutics Inc- expect to deliver top-line data on ORR endpoint earlier than anticipated, now expected in Q2 of 2018.  Full Article

TG Therapeutics announces successful outcome from first pre-planned interim analysis
Thursday, 10 Aug 2017 07:30am EDT 

Aug 10 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial.TG Therapeutics Inc - ‍DSMB recommends continued enrollment in TGR-1202 + TG-1101 arm and no further enrollment into single agent TGR-1202 arm​.TG Therapeutics Inc - ‍single agent TGR-1202 arm will be replaced with triple combination of TG-1101, TGR-1202 and bendamustine​.  Full Article

BRIEF-TG Therapeutics, Novimmune Announce Global Agreement For Development And Commercialization Of Anti-CD47/ Anti-CD19 bispecific antibody

* TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY